New therapies in soft tissue sarcoma

Expert Opinion on Emerging Drugs

Volumn 15, Issue 2, 2010, Pages 237-248

  Vincenzi, Bruno ^a   Frezza, Anna Maria ^a   Santini, Daniele ^a   Tonini, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Anthracycline; Ifosfamide; Mesenchymal neoplasm; MTOR inhibitors; Small tyrosine kinase inhibitors; Soft tissue sarcoma

Indexed keywords

AMG 479; BROSTALLICIN; CP 751871; DEFOROLIMUS; DOCETAXEL; DOXORUBICIN; ERIBULIN; EVEROLIMUS; GEMCITABINE; IFOSFAMIDE; NVP AEW 541; PAZOPANIB; PEMETREXED; PLACEBO; RAPAMYCIN; SORAFENIB; TRABECTEDIN;

ADJUVANT THERAPY; ADVANCED CANCER; ALOPECIA; ANEMIA; ANGIOSARCOMA; ANOREXIA; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CHONDROSARCOMA; CLINICAL TRIAL; CONTINUOUS INFUSION; DESMOPLASTIC SMALL ROUND CELL TUMOR; DESQUAMATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; EWING SARCOMA; FATIGUE; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HAIR DISCOLORATION; HAND FOOT SYNDROME; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KAPOSI SARCOMA; LEIOMYOSARCOMA; LEUKOPENIA; LIPOSARCOMA; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; MYXOSARCOMA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; PROGNOSIS; REVIEW; SEPTICEMIA; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMATITIS; SYNOVIAL SARCOMA; THROMBOCYTOPENIA; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; HUMANS; SARCOMA; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME;

EID: 77952847887     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728211003592108     Document Type: Review

References (77)

1. Ries LAG, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975-2005, National Cancer Institute. Bethesda, MD. Available from: http://seer.cancer.gov/csr/ 1975-2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008
2. Wei L, Song XR, Wang XW, et al. Expression of MDR1 and GST-pi in osteosarcoma and soft tissue sarcoma and their correlation with chemotherapy resistance. Zhonghua Zhong Liu Za Zhi 2006;28(6):445-448
3. Pasello M, Michelacci F, Scionti I, et al. Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. Cancer Res 2008;68(16):6661-6668
4. Pisters P. Staging and prognosis. In: Pollock RE, editor. American Cancer Society Atlas of Clinical Oncology: Soft tissue sarcomas. BC Decker, Inc., Hamiliton, Ontario; 2002. p. 80-88
5. Gottlieb JA, Baker LH, Quagliana JM, et al. Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide. Cancer 1972;30:1632-1638
6. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982;96:133-139
7. Samuels BL, Vogelzang NJ, Ruane M, Simon MA. Continuous venous infusion of doxorubicin in advanced sarcomas. Cancer Treat Rep 1987;71:971
8. Shapira J, Gotfried M, Lishner M, Ravid M. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen: a prospective randomized evaluation. Cancer 1990;65:870-873
9. Judson I, Radford JA, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL(R)/ CAELYX(R)) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001;37:870-877
10. Bramwell VH, Mouridsen HT, Santoro A, et al. Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 1993;31(Suppl 2):S180-4
11. Lorigan P, Verweij J, Papai Z, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 2007;25(21):3144-3150
12. Gortzak E, Azzarelli A, Buesa J, et al. A randomised phase II study on neoadjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer 2001;37:1096-1103
13. Peraiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008;113(3):573-581
14. Zewail-Foote M, Hurley LH. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 1999;42:2493-2497
15. Bonfanti M, La Valle E, Fernandez Sousa Faro JM, et al. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des 1999;14:179-186
16. Jin S, Gorfajn B, Faircloth G, et al. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci USA 2000;97:6775-6779
17. Damia G, Silvestri S, Carrassa L, et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 2001;92:583-588
18. Erba E, Bergamaschi D, Bassano L, et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 2001;37:97-105
19. Takebayashi Y, Pourquier P, Zimonjic DB, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotideexcision repair. Nat Med 2001;7:961-966
20. Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004;22:1480-1490
21. Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005;23:576-584
22. Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004;22:890-899
23. Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009;27(25):4188-4196
24. Merimsky O, Meller I, Flusser G, et al. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol 2000;45:177-181
25. Okuno S, Ryan LM, Edmonson JH, et al. Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group. Cancer 2003;97:1969-1973
26. Patel SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001;19:3483-3489
27. Grosso F, Dileo P, Sanfilippo R, et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer 2006;42(10):1484-1490
28. Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007;8:595-602
29. Grosso F, Forni C, Frapolli R, et al. Sensitivity of myxoid-round cell liposarcoma (MRCL) to trabectedin (T) may be related to a direct effect on the fusion transcript. ASCO Meeting Abstracts. 2007;25:10000
30. Herrero AB, Martin-Castellanos C, Marco E, et al. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 2006;66:8155-8162
31. Schoffski P, Grosso F, Taron M. DNA repair functionality as a molecular signature for sensitivity(S)/resistance(R) in sarcoma patients (pts) treated with trabectedin (ET-743, Yondelis-). 98th AACR Annual Meeting; 14-18 April 2007; Los Angeles, CA, USA
32. Van Hoesel QG, Verweij J, Catimel G, et al. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 1994;5:539-542
33. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 2007;25(19):2755-2763
34. Okuno S. Mammalian target of rapamycin inhibitors in sarcomas. Curr Opin Oncol 2006;18:360-362
35. Magenau JM, Schuetze SM. New targets for therapy of sarcoma. Curr Opin Oncol 2008;20:400-406
36. Campistol JM, Schena FP. Kaposi's sarcoma in renal transplant recipients-the impact of proliferation signal inhibitors. Nephrol Dial Transplant 2007;22(Suppl 1):i17-22
37. Montaner S. Akt/TSC/mTOR activation by the KSHV G protein-coupled receptor: emerging insights into the molecular oncogenesis and treatment of Kaposi's sarcoma. Cell Cycle 2007; 6:438-443
38. Guenova E, Metzler G, Hoetzenecker W, et al. Classic mediterranean Kaposi's sarcoma regression with sirolimus treatment. Arch Dermatol 2008;144:692-693
39. Merimsky O, Jiveliouk I, Sagi-Eisenberg R. Targeting mTOR in HIV-negative classic Kaposi's sarcoma. Sarcoma 2008;2008:825093
40. Wiederrecht GJ, Sabers CJ, Brunn GJ, et al. Mechanism of action of sirolimus: new insights into the regulation of G1-phase progression in eukaryotic cells. Prog Cell Cycle Res 1995;1:53-71
41. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1a expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22:7004-7014
42. Mayerhofer M, Valent P, Sperr WR, et al. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 2002;100:3767-3775
43. Werner H, Bruchim I. The insulin-like growth factor-I receptor as an oncogene. Arch Physiol Biochem 2009;115(2):58-71
44. Scotlandi K, Picci P. Targeting insulin-like growth factor 1 receptor in sarcomas. Curr Opin Oncol 2008;20(4):419-427
45. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6(7):2012-2021
46. Yu C, Bruzek LM, MengXW, et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005;24:6861-6869
47. Pezzola S, Antonini G, Geroni C, et al. The role of glutathione S-transferases in the mechanism of Brostallicin activation. Biochemistry 2010;49(1):226-235
48. Guirouilh-Barbat J, Zhang YW, Pommier Y. Induction of glutathione-dependent DNA double-strand breaks by the novel anticancer drug brostallicin. Mol Cancer Ther 2009;8(7):1985-1994
49. Seletsky BM, Wang Y, Hawkins LD, et al. Structurally simplified macrolactone analogues of halichondrin B. Bioorg Med Chem Lett 2004;14:5547-5550
50. Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005;4:1086-1095
51. Zhao R, Babani S, Gao F, et al. The mechanism of transport of the multitargeted antifolate. MTA-LY231514, and its cross-resistance pattern in cell with impaired transport of methotrexate. Clin Cancer Res 2000;6:3687-3695
52. Shih C, Mendelsohn LG, Chen VJ, Schultz RM. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul 1998;38:135-152
53. Schultz RM, Patel VF, Worzalla JF, Shih CA. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res 1999;19:437-443
54. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo(2,3-d) pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-2011
55. Mita MM, Mita AC, Chu QS, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 2008;26(3):361-367
56. Chawla SP, Tolcher AW, Staddon AP, et al. Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: update of phase II trial [10076]. 2007 ASCO Annual Meeting
57. Deforolimus (AP23573) in treatment of sarcoma; SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Deforolimus) study. Available from: http://www.clinicaltrials.gov/ct2/ show/NCT00538239
58. Murphy JD, Spalding AC, Somnay YR, et al. Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature. Clin Cancer Res 2009;15(2):589-596
59. Kull FC, Jacobs S, Su Y-F, et al. Monoclonal antibodies to receptors for insulin and somatomedin-c. J Biol Chem 1983;258:6561-6566
60. Kalebic T, Tsokos M, Helman LJ. In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34. Cancer Res 1994;54:5531-5534
61. Fong PC, Molife RL, Spicer J, et al. Phase I trial involving the pharmacodynamic study of circulating tumour cells, of CP-751,871 (C), a monoclonal antibody against the insulin-like growth factor-I receptor, with docetaxel in patients with advanced cancer. EurJ Cancer Suppl 2006;4:61
62. Manara MC, Landuzzi L, Nanni P, et al. Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma. Clin Cancer Res 2007;13:1322-1330
63. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009;27(19):3126-3132
64. Wilhelm SM, Carter C, Tang L, et al. BAY43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109
65. Levy AP, Pauloski N, Braun D, et al. Analysis of transcription and protein expression changes in the 786-O human renal cell carcinoma tumor xenograft model in response to treatment with the multi-kinase inhibitor sorafenib (BAY 43-9006). Proc Am Assoc Cancer Res 2006;47:213-214
66. Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009;27(19):3133-3140
67. Vincenzi B, Santini D, Addeo R, et al. Early skin toxicity as a molecular marker of efficacy for tumor control in HCC patients treated with sorafenib. ESMO Annual Meeting 2009
68. Ten Tije AJ, Verweij J, Sparreboom A, et al. Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer. Clin Cancer Res 2003;9(8):2957-2964
69. Leahy M, Ray-Coquard I, Verweij J, et al. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2007;43(2):308-315
70. Tan AR, Rubin EH, Walton DC, et al. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 2009;15(12):4213-4219
71. Goel S, Mita AC, Mita M, et al. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 2009;15(12):4207-4212
72. Takimoto CH, Hammond-Thelin LA, Latz JE, et al. Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. Clin Cancer Res 2007;13(9):2675-2683
73. Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009;15(12):4220-4227
74. Clark JW, Eder JP, Ryan D, et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11:5472-5480
75. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/ 7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:1855-1861
76. Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:1688-1694
77. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-972